PMID- 11963288
OWN - NLM
STAT- MEDLINE
DCOM- 20020624
LR  - 20051116
IS  - 0870-2551 (Print)
IS  - 0870-2551 (Linking)
VI  - 21
IP  - 2
DP  - 2002 Feb
TI  - Update of the management of venous thromboembolism.
PG  - 183-99
AB  - Venous thromboembolism is the third most common cardiovascular disease. Its 
      treatment is based in unfractionated heparin (UFH), but the advance of low 
      molecular weight heparins, with clinical efficacy at least similar to UFH and 
      better safety profile, have changed the therapeutic consensus. The highly 
      relevant physiopathologic information has contributed to understand the 
      paradoxical thrombotic mechanisms associated with heparin induced 
      thrombocytopenia. New drugs, such as danaparoid sodium, lepirudin and argatroban, 
      are an alternative to anticoagulation by heparin when this adverse reaction 
      occurs. Another relevant progress was the determination of optimal duration of 
      oral anticoagulation in order to prevent thromboembolic recurrences. In the 
      meantime, other pharmacological approaches (thrombolytics and antiplatelet 
      agents) have been assessed in several trials of limited value outcomes. 
      Prophylactic measures like graduated compression stockings/intermittent external 
      pneumatic compression and inferior vena cava filters have shown efficacy in 
      primary and secondary prevention in patients with different risks of 
      thromboembolic recurrence.
FAU - Rodrigues, H Luz
AU  - Rodrigues HL
AD  - Instituto de Farmacologia e Terapeutica, Faculdade de Medicina, Lisboa.
FAU - Brandao, E Serra
AU  - Brandao ES
FAU - Lima, B Silva
AU  - Lima BS
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Portugal
TA  - Rev Port Cardiol
JT  - Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de 
      Cardiologia = Portuguese journal of cardiology : an official journal of the 
      Portuguese Society of Cardiology
JID - 8710716
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Administration, Oral
MH  - Anticoagulants/administration & dosage
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Heparin/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Thrombectomy
MH  - Thrombolytic Therapy
MH  - Vena Cava Filters
MH  - Venous Thrombosis/epidemiology/prevention & control/therapy
RF  - 97
EDAT- 2002/04/20 10:00
MHDA- 2002/06/25 10:01
CRDT- 2002/04/20 10:00
PHST- 2002/04/20 10:00 [pubmed]
PHST- 2002/06/25 10:01 [medline]
PHST- 2002/04/20 10:00 [entrez]
PST - ppublish
SO  - Rev Port Cardiol. 2002 Feb;21(2):183-99.